Followers | 2543 |
Posts | 250734 |
Boards Moderated | 34 |
Alias Born | 05/06/2014 |
Wednesday, February 11, 2015 7:45:42 PM
Welcome to the PharmaCyte BioTech Inc. (PMCB)! BEFORE getting into the below I'd like to direct your attention to the Intro Page (aka iBox), which can be found at the top of the page on the right hand corner. Make sure it says, "SHOW INTRO" I encourage EVERYONE to visit the iBox (and to SHARE this with new folks), so others can find "some" easier DD.
http://investorshub.advfn.com/PharmaCyte-Biotech-Inc-PMCB-5034/
1. FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment
Read more at: http://globenewswire.com/news-release/2014/12/22/693421/10113176/en/FDA-Grants-Orphan-Drug-Designation-to-Nuvilex-for-Pancreatic-Cancer-Treatment.html#sthash.S59r45U0.dpuf
2. PharmaCyte Biotech Analyst Report Issued by BrokerBank Securities, Inc.
Read more at: http://www.prnewswire.com/news-releases/pharmacyte-biotech-analyst-report-issued-by-brokerbank-securities-inc-300033999.html
3. PharmaCyte Biotech's International Diabetes Consortium Sets Path Forward to Develop Novel Treatment for Diabetes
Read more at: http://globenewswire.com/news-release/2015/02/10/704889/10119399/en/PharmaCyte-Biotech-s-International-Diabetes-Consortium-Sets-Path-Forward-to-Develop-Novel-Treatment-for-Diabetes.html#sthash.a500SFqx.dpuf
4.PharmaCyte Biotech's Pancreatic Cancer Treatment Named as Near-Term Approach to Rising Pancreatic Cancer Rates
Read more at: http://globenewswire.com/news-release/2015/01/15/697687/10115663/en/PharmaCyte-Biotech-s-Pancreatic-Cancer-Treatment-Named-as-Near-Term-Approach-to-Rising-Pancreatic-Cancer-Rates.html#sthash.fiztoExn.dpuf
5. PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation
Read more at: http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537#ixzz3Py5xyHCy
6. New Approaches Tackle Rising Pancreatic Cancer Rates
Read more at: http://jnci.oxfordjournals.org/content/106/12/dju417.full
Blessing and Love!
Go $PMCB
Pistol Pete!
"Patience, persistence and perspiration make an unbeatable combination for success."
Recent PMCB News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 10:06:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:28 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/04/2023 08:40:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:01:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/31/2023 09:18:17 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM